Cholinesterase inhibitors for mild cognitive impairment

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 7, 2012, Pages

  Russ, Tom C ^a   Morling, Joanne R ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

CHEMICALLY INDUCED DISORDER; DEMENTIA; DIARRHEA; DISEASE COURSE; HUMAN; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VOMITING;

CHOLINESTERASE INHIBITORS; DEMENTIA; DIARRHEA; DISEASE PROGRESSION; HUMANS; MILD COGNITIVE IMPAIRMENT; NAUSEA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VOMITING;

EID: 84872460554     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009132.pub2     Document Type: Article

References (87)

1. Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009;72:1555-61. x-wiley/crsRef/3235497
2. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurology 2007;6:501-12. x-wiley/crsRef/3235499
3. Koontz J, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. American Journal of Alzheimer's Disease and Other Dementias 2005;20:295-302. x-wiley/crsRef/3235501
4. Narasimhalu K, Effendy S, Sim CH, Lee JM, Chen I, Hia SB, et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurologica Scandinavica 2010;121:217-24. x-wiley/crsRef/3235503
5. Peters O, Lorenz D, Fesche A, Schmidtke K, Hüll M, Perneczky R, et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. Journal of Nutrition, Health & Aging 2012;16:544-8. x-wiley/crsRef/3235505
6. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine 2005;352:2379-88. x-wiley/crsRef/3235507
7. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004;63:651-7. x-wiley/crsRef/3235509
8. Winblad B, Gauthier S, Scinto L. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024-35. x-wiley/crsRef/3235511
9. Winblad B, Gauthier S, Scinto L. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024-35. x-wiley/crsRef/3235513
10. Winblad B, Gauthier S, Scinto L. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024-35. x-wiley/crsRef/3235515
11. Anon. Study of donepezil for MCI shows only minor improvement in patients with mild cognitive impairment. Geriatric Psychopharmacology Update 2009;13(8):1. x-wiley/crsRef/3235517
12. Barnes DE, Yaffe K, Petersen RC, Thomas RG, Thal LJ. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine 2005;352:2379-88. x-wiley/crsRef/3235519
13. Bokde A, Lopz-Bayo P, Meindl T, Teipel SJ, Reiser M, Moller HJ, et al. Effect of rivastigmine in a double-blind study in MCI subjects: a functional magnetic resonance imaging study. International Journal of Neuropsychopharmacology 2008;11:29-30. x-wiley/crsRef/3235521
14. Chen X, Magnott VA, Duff K, Boles Ponto LL, Schultz SK. Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits. Journal of Neuropsychiatry & Clinical Neurosciences 2006;18(2):175-85. x-wiley/crsRef/3235523
15. Crane PK, Doody RS. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009;73(18):1514-5. x-wiley/crsRef/3235525
16. Djalalov S, Yong JHE, Saposnik G, Hoch J. Is genetic testing in combination with preventive donepezil (ARICEPT) treatment for patients with mild cognitive impairment cost-effective? (ISPOR 14th Annual International Meeting Orlando, FL United States). Value in Health 2009;12(3):A191. x-wiley/crsRef/3235527
17. Dubois B, Sarazin M, Lehericy S, Chupin M, Tonelli I, Garnero L, et al. Effects of donepezil on structural MRI and clinical markers in patients with amnestic mild cognitive impairment: a randomized, placebo-controlled trial (Alzheimer's Association International Conference on Alzheimer's Disease, Vienna). Alzheimer's and Dementia 2009;5(4 Suppl 1):269. x-wiley/crsRef/3235529
18. E2020-A001-412. A one year, multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride in subjects with mild cognitive impairment (MCI), 2005. www.mrw.interscience.wiley.com/cochrane/clcentral/articles/394/CN-00519394/frame.html (accessed 3 August 2012). x-wiley/crsRef/3235531
19. Ferris S, Darreh-Shori T, Lane R. Effects of rivastigmine on brain white matter volume in mild cognitive impairment (MCI) (Alzheimer's Association International Conference on Alzheimer's Disease, Vienna). Alzheimer's and Dementia 2009;5(4 Suppl 1):332. x-wiley/crsRef/3235533
20. GAL-COG-3002. An analysis of mortality in subjects who participated in three studies of galantamine in mild cognitive impairment (MCI), 2005. clinicaltrials.gov/ct2/show/NCT00297414 (accessed 3 August 2012). x-wiley/crsRef/3235535
21. GAL-INT-11. A randomised placebo-controlled trial to evaluate the efficacy and safety of galantamine in patients with minimal cognitive impairment (MCI) clinically at risk for development of probable Alzheimer's disease, 2003. www.mrw.interscience.wiley.com/cochrane/clcentral/articles/132/CN-00452132/frame.html (accessed 3 August 2012). x-wiley/crsRef/3235537
22. GAL-INT-18. A randomized double-blind, placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probable Alzheimer's disease, 2004. www.mrw.interscience.wiley.com/ cochrane/clcentral/articles/227/CN-00744227/frame.html. x-wiley/crsRef/3235539
23. Gold M, Wang D, Truyen L. Galantamine for the treatment of mild cognitive impairment: 2 double-blind, placebo-controlled studies. International Psychogeriatrics 2003;15(Suppl 2):259. x-wiley/crsRef/3235541
24. Grundman M. MCI trial with vitamin E and donepezil. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, 2000. www.mrw.interscience.wiley.com/cochrane/clcentral/articles/212/CN-00404212/frame.html (accessed 3 August 2012). x-wiley/crsRef/3235543
25. Jack CR, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, et al. Longitudinal MRI findings from the Vitamin E and Donepezil Treatment Study for MCI. Neurobiology of Aging 2008;29(9):1285-95. x-wiley/crsRef/3235545
26. Johnson & Johnson Pharmaceutical Research and Development. A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in patients with mild cognitive impairment (MCI) clinically at risk for development of clinically probable Alzheimer's disease, 2005. clinicaltrials.gov/ct2/show/NCT00236574 (accessed 3 August 2012). x-wiley/crsRef/3235547
27. Jones W, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. International Journal of Geriatric Psychiatry 2004;19(1):58-67. x-wiley/crsRef/3235549
28. Kopchak O. Efficacy of citicoline in the treatment of patients with vascular cognitive impairment (20th Meeting of the European Neurological Society, Berlin). Journal of Neurology 2010;257:S128. x-wiley/crsRef/3235551
29. Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 2009;72(24):2115-21. x-wiley/crsRef/3235553
30. Montero-Odasso M, Wells JL, Borrie MJ, Speechley M. Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial. BMC Neurology 2009;9:42. x-wiley/crsRef/3235555
31. Onofrj M, Thomas A, Iacono D, Lucino AL, Di Iorio A. The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia. Clinical Neuropharmacology 2003;26(5):239-51. x-wiley/crsRef/3235557
32. Ownby R. Donepezil and vitamin E for mild cognitive impairment. Current Psychiatry Reports 2006;8(1):9. x-wiley/crsRef/3235559
33. Ozenli Y, Yagci D, Karaca S. Efficacy of donepezil on cognitive functions in mild cognitive impairment. Klinik Psikofarmakoloji Bulteni 2007;17(2):62-7. x-wiley/crsRef/3235561
34. Panza F, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Chiloiro R, et al. Effect of donepezil on the continuum of depressive symptoms, mild cognitive impairment, and progression to dementia. Journal of the American Geriatrics Society 2010;58(2):389-90. x-wiley/crsRef/3235563
35. Petersen RC, Thomas RG, Thal LJ. "Vitamin E and donepezil for the treatment of mild cognitive impairment": the authors reply. New England Journal of Medicine 2005;353(9):951-2. x-wiley/crsRef/3235565
36. Petrella JR, Prince SE, Krishnan S, Husn H, Kelley L, Doraiswamy PM. Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging. American Journal of Neuroradiology 2009;30(2):411-6. x-wiley/crsRef/3235567
37. Politis AM, Theleritis C, Passa M, Maillis A, Papadimitriou GN. Improvement of cognitive dysfunction with high-dose rivastigmine. Psychosomatics 2010;51(1):89-90. x-wiley/crsRef/3235569
38. Saykin AJ, Wishart HA, Rabin LA, Flashman LA, McHugh TL, Mamourian AC, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 2004;127(7):1574-83. x-wiley/crsRef/3235571
39. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Archives of Neurology 2004;61(12):1852-56. x-wiley/crsRef/3235573
40. Shua-Haim JR, Shua-Haim V, Comsti E. Donepezil in the treatment of age-acquired cognitive deficit. Clinical Geriatrics 2001;9(9):35. x-wiley/crsRef/3235575
41. Turon-Estrada A, Lopez-Pousa S, Gelada-Batlle E, Garre-Olmo J, Lozano-Gallego M, Hernandez-Ferrandiz M, et al. Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer's disease over a six-month period [Tolerancia y acontecimientos adversos del tratamiento con inhibidores de la acetilcolinesterasa en una muestra clínica de pacientes con enfermedad de Alzheimer de gravedad mínima y leve durante un perÍodo de seis meses]. Revista de Neurologia 2003;36:421-4. x-wiley/crsRef/3235577
42. Vandesquille M, Chauveau F, Decros-Tesolin B, Pierard C, Sebban S, Mouthon F, et al. Potentiation of donepezil efficiency profile by connexin inhibitors in age-related cognitive impairment. European Neuropsychopharmacology Conference: 2012 ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe, Nice, France. 2012. x-wiley/crsRef/3235579
43. Wang LN, Wang W, Zhang XH, Ma L, Yin H, Li DJ. An interventional study on amnestic mild cognitive impairment with small dose donepezil. Zhonghua Nei Ke Za Zhi 2004;43(10):760-3. x-wiley/crsRef/3235581
44. Wang L, Harms MP, Staggs JM, Xiong C, Morris JC, Csernansky JG, et al. Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. Archives of Neurology 2010;67:99-106. x-wiley/crsRef/3235583
45. Yesavage JA, Friedman L, Ashford JW, Kraemer HC, Mumenthaler MS, Noda A, et al. Acetylcholinesterase inhibitor in combination with cognitive training in older adults. Journals of Gerontology Series B: Psychological Sciences & Social Sciences 2008;63B(5):P288-94. x-wiley/crsRef/3235585
46. 24-week, randomized, double-blind, placebo-controlled, parallel group study of the Exelon® [rivastigmine] transdermal patch in 120 APOE e4 positive amnestic MCI patients, 2011. http://clinicaltrials.gov/ct2/show/NCT01602198 (accessed 3 August 2012). x-wiley/crsRef/3235587
47. Agrell B, Dehlin O. The clock-drawing test. Age and Ageing 1998;27:399-403.
48. Albert MS, DeKosky ST, Dickson D, Dubois, B, Feldman, HH, Fox, NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7:270-9.
49. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005593]
50. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD001190.pub2]
51. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD001191.pub2]
52. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary No. 63. British National Formulary, 63rd Edition. London: BMJ Publishing Group, March 2012.
53. Braak H, Braak E. Neuropathological Stageing of Alzheimer-related changes. Acta Neuropathologica 1991;82:239-59.
54. D'Elia. Color Trails Test: Professional Manual. PAR, 1996.
55. Dawe B, Procter A, Philpot M. Concepts of mild memory impairment in the elderly and their relationship to dementia - a review. International Journal of Geriatric Psychiatry 1992;7(7):473-9.
56. Diniz BS, Pinto JA, Gonzaga MCG. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer’s disease. European Archives of Psychiatry and Clinical Neuroscience 2009;259:248-56.
57. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7.
58. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12:189-98.
59. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11(Suppl 2):S33-9.
60. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet 2006;367:1262-70.
61. Heinik J. V. A. Kral, the Montreal Hebrew Old People's Home, and benign senescent forgetfulness. History of Psychiatry 2006;17:313-32.
62. Heinik J. V. A. Kral and the origins of benign senescent forgetfulness and mild cognitive impairment. International Psychogeriatrics 2010;22:395-402.
63. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
64. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. An analysis of mortality in subjects who participated in three studies of galantamine in mild cognitive impairment. CR004240.
65. Kluger A, Ferris SH, Golomb G, Mittelman MS, Reisberg B. Neuropsychological prediction of decline to dementia in non-demented elderly. Journal of Geriatric Psychiatry and Neurology 1999;12:168-79.
66. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. Oxford University Press, 2004.
67. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD001747.pub3]
68. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65(12):1863-72.
69. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44.
70. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging – Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7:263-9.
71. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11(Suppl 2):S13-21.
72. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-4.
73. O'Brien JT. Mild cognitive impairment. In: Jacoby R, Oppenheimer C, Dening T, Thomas A editor(s). Oxford Textbook of Old Age Psychiatry. Oxford: Oxford University Press, 2008.
74. Office for National Statistics. Key Population and Vital Statistics. Basingstoke: Palgrave Macmillan, 2006.
75. Petersen RC. Normal aging, mild cognitive impairment, and early Alzheimer's disease. Neurologist 1995;1:326-44.
76. Petersen RC, Amith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999;56:303-8.
77. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, et al. Neuropathologic features of amnestic mild cognitive impairment. Archives of Neurology 2006;63:665-72.
78. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Medicine 2007;4(11):e338.
79. Reid LM, MacLullich AMJ. Subjective memory complaints and cognitive impairment in older people. Dementia and Geriatric Cognitive Disorders 2006;22:471-85.
80. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
81. Ritchie K. Mild cognitive impairment: an epidemiological perspective. Dialogues in Clinical Neuroscience 2004;6:401-8.
82. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43(2):250-60.
83. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry 1984;141(11):1356-64.
84. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain 1988;111(3):695-718.
85. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11(Suppl 2):S22-32.
86. Sobów T, Kłoszewska I. Cholinesterase Inhibitors in mild cognitive impairment: a meta-analysis of randomized controlled trials [Inhibitory cholinesterazy w łagodnych zaburzeniach poznawczych: metaanaliza badań z randomizacją i z grupą kontrolną otrzymującą placebo]. Neurologia i Neurochirurgia Polska 2007;41:13-21.
87. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine 2004;256:240-6.